Dr GUILLONNEAU is Director of Research CNRS, head of team 2 at the Center of Research in Transplantation and Translational Immunology (CR2TI) in Nantes, France and director of the FOCIS Center of Excellence Nantes University. After a Postdoc in the laboratory of Nobel Laureate Prof. Doherty in Australia, she moved to Nantes and obtained a permanent position at the CNRS. She currently leads a team that focuses on the biology of CD8+ Tregs, investigates their clinical potential and develops new therapies to replace conventional immunosuppression in the context of transplantation and immune-related diseases. She is the inventor of 20 patents and co-founder and scientific advisor of the start-up AbolerIS Pharma.
| When | Session | Talk Title | Room |
|---|---|---|---|
|
Fri-24 11:30 - 12:30 |
Oral Abstract Session — Parallel Session 13: Next-generation strategies in cell and gene therapy 2 | Advancing CD8+ Treg cell therapy to the clinic for the treatment of kidney transplanted patients | Hall A2-3 |